Optimal IGF-1 Level: Why Longevity Researchers Disagree

IGF-1 (insulin-like growth factor 1) drives cell proliferation and suppresses autophagy, the cell's own cleanup process. That tradeoff, more growth versus more cleanup, is where longevity researchers split. Valter Longo targets a low IGF-1 for cancer-risk reduction; Peter Attia frames it as a balance against muscle loss. Below is each position, attributed to source.

AI-curated · Expert-attributed

Compiled by AI from the named experts’ own public statements, with every figure attributed to its source. These are individual expert protocols, not clinical guidelines or FixFirst medical advice. Evidence & methodology

2 expert positions, attributed to source Covers the growth-hormone-peptide connection Free 45-second read on your own results

Two researchers, two different priorities

Longo optimises against cancer risk. Attia optimises against both cancer risk and muscle loss simultaneously, which is why he doesn't cite a single target number the way Longo does.

This page is part of FixFirst's Longevity blood markers series. IGF-1 is not yet part of FixFirst's supported marker set; this page is informational content on what these researchers have said publicly, not a marker the analyzer currently checks. For the broader question of how "optimal" targets like these compare to standard lab reference ranges, see the optimal blood test ranges guide.

Growth hormone secretagogue peptides (compounds that stimulate the pituitary to release more growth hormone) raise IGF-1 as a downstream effect, since growth hormone triggers the liver to produce IGF-1. If someone is using a GH secretagogue peptide, IGF-1 is the standard lab marker used to monitor its effect on the body, the same marker Longo and Attia are each citing a target for below. This page covers what IGF-1 measures and how to read a result; it does not cover which peptide to use, at what dose, or where to source one, those are questions for a physician overseeing that specific protocol.

The two positions

Longo's research is built on populations with naturally low IGF-1. Attia's framing comes from treating IGF-1 as one input among several (muscle mass, VO2 max, cancer risk factors) rather than a number to independently optimise.

Cluster 1 of 1

Where they disagree

Both agree IGF-1 drives cell growth and suppresses autophagy. They disagree on what to do with that tradeoff.

Core Usually in a standard panel Ask Request specifically

Ask

Valter Longo — targets ~100–150 ng/mL

Longo cites population data (Laron syndrome, Okinawan longevity cohorts) showing naturally low IGF-1 correlates with dramatically lower cancer rates and longer lifespan. He argues that optimising IGF-1 for muscle building, the more common Western framing, trades short-term gains for higher cellular-ageing and cancer risk. His primary lever is dietary: a periodic Fasting Mimicking Diet and reduced animal protein, particularly dairy and red meat, both of which lower IGF-1.

Ask

Peter Attia — monitors for balance, no fixed target

Attia treats IGF-1 as a two-edged marker: useful for muscle protein synthesis, but a driver of cell growth that can accelerate cancer risk if chronically elevated. He does not optimise for a single number, tracking the trend instead alongside muscle mass, VO2 max, and personal cancer risk factors. His primary lever is adequate protein intake for muscle preservation, not IGF-1 restriction.

Frequently asked questions

What is a normal IGF-1 level?

IGF-1 reference ranges vary substantially by age, sex, and the specific lab's assay, and are typically reported alongside an age-and-sex-adjusted range on the lab report itself rather than a single universal number. Valter Longo has cited roughly 100–150 ng/mL as a longevity-optimised target, lower than what many labs consider mid-range for younger adults.

Does a higher IGF-1 always mean more muscle?

IGF-1 supports muscle protein synthesis, but the relationship isn't purely linear, and Attia specifically frames IGF-1 as a two-edged marker rather than a simple 'more is better' number for muscle. Resistance training and adequate protein intake support muscle growth through multiple pathways, not IGF-1 alone.

Do growth hormone peptides raise IGF-1?

Growth hormone secretagogue peptides work by stimulating the pituitary to release more growth hormone, and growth hormone triggers the liver to produce IGF-1, so yes, IGF-1 typically rises as a downstream effect. IGF-1 is the standard blood marker used to monitor that effect, since growth hormone itself is harder to measure reliably from a single blood draw due to its pulsatile release pattern.

Should I test IGF-1 if I'm not using growth hormone peptides?

IGF-1 is not a standard part of most blood panels and is typically ordered when there's a specific reason: monitoring a GH secretagogue's effect, investigating a suspected pituitary or growth hormone disorder, or, for the researchers on this page, as part of a broader longevity-focused panel. It's a discussion to have with a physician rather than a default test to order on your own.

Once you have your results

IGF-1 isn't part of a standard panel, but the metabolic markers most relevant to overall longevity, HbA1c, lipids, and inflammation, usually are.

Upload to FixFirst

Get your top 3 priorities ranked in 45 seconds

Upload your PDF and FixFirst checks all 86 markers against standard clinical thresholds, adjusted for your sex and context, then ranks what matters most.

Upload My Report →

More longevity marker pages

See the full Longevity section

Peter Attia's full panel, Andrew Huberman's markers, and GLP-1 before-and-after tracking, each attributed to its source.

Browse the Longevity section

Optimal IGF-1 Level: Why Longevity Researchers Disagree

Two researchers, two different priorities

The two positions

Frequently asked questions

Once you have your results

See where your metabolic and inflammatory markers stand.